Non-regulatory announcement

Verici Dx plc

("Verici Dx" or the "Company") 

New data to be presented at American Transplant Conference

Important potential role of Tutivia^TM as a novel risk assessment tool in the context of delayed graft function ("DGF")

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it will attend the American Transplant Congress ("ATC") in Philadelphia hosted by the American Society of Transplantation and the American Society of Transplant Surgeons from 1-5 June 2024. We look forward to sharing our work on "Performance of Next-Gen Sequencing Biomarker Tutivia^TM in the Setting of Kidney Delayed Graft Function" on Saturday 1 June 2024, as well as meeting with others to discuss ideas and opportunities at ATC_Booth-215.

ATC provides a forum for the exchange of new scientific data and clinical information relevant to solid organ and tissue transplantation. The event brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals and other transplant professionals.

Commenting on the conference, Dr. Joshua Lee, VP Medical Affairs said:

"DGF is a condition that can lead to a higher risk of rejection. Identifying which patients are likely to experience rejection in this population is an unmet need in transplantation. Verici Dx is excited to present findings in this population from our clinical trial at this prestigious conference.

ATC in Philadelphia is such a great venue to bring together the global transplant community. We are looking forward to discussions in the halls and seeing friends in the community, as well as learning about new developing approaches to treatments and diagnostics that can make the lives of transplant patients better." 

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.